Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day
NCT ID: NCT02397551
Last Updated: 2018-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2015-03-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dual Trigger Versus Booster Dose of HCG
NCT02397642
Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration
NCT02330770
Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles
NCT04008966
Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS
NCT02827656
Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure
NCT02329197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Small doses of HCG
Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
IVF/ICSI
Human Chorionic Gonadotropin
Given in different doses and timing to support the luteal phase
Booster HCG dose
Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
IVF/ICSI
Human Chorionic Gonadotropin
Given in different doses and timing to support the luteal phase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IVF/ICSI
Human Chorionic Gonadotropin
Given in different doses and timing to support the luteal phase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* More than 14 MII oocytes
* Estradiol more than 3500 pg/ml on day of trigger
Exclusion Criteria
* Normal or poor responders
20 Years
37 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nile Ivf Center, Cairo, Egypt
OTHER
Adam International Hospital
OTHER
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yasmin Ahmed Bassiouny
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarwat Ahwany, MD
Role: STUDY_DIRECTOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)
Cairo, , Egypt
Adam International hospital
Giza, , Egypt
Nile IVF center
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.